FDA taps CRO Vince & Associates for $5M bioequivalent contract

Kansas CRO Vince & Associates Clinical Research is on the up-and-up thanks to some federal contracts, and its latest is a 5-year deal with the FDA worth up to $5 million.

Under the agreement, Vince & Associates will examine the bioequivalence of generics that have resulted in past adverse events, the company said, handling study design, protocol development and patient recruitment. Brad Vince, the company's president and medical director, said his outfit will also help conduct the studies. "We are truly excited to partner with the FDA to help address agency concerns with product-substitution issues," Vince said in a statement.

The latest federal deal follows Vince & Associates' 5-year agreement with the National Institute on Drug Abuse, part of the National Institutes of Health. That deal, worth up to $10 million, tasks the company with researching investigational treatments for substance abuse, including biologics, enzymes and vaccines, Kansas City Business Journal reported.

The company recently launched a multimillion-dollar, 90-bed clinical development unit to augment its Kansas campus, and, in its 10 years in business, Vince & Associates has conducted more than 400 trials for about 80 pharmaceutical companies.

- read Vince & Associates' statement
- check out the Business Journal's article

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.